BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deng Y, Du Y, Zhang Q, Han X, Cao G. Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and hepatocellular carcinoma. Cancer Lett. 2014;343:161-171. [PMID: 24120759 DOI: 10.1016/j.canlet.2013.09.041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Liao R, Fu YP, Wang T, Deng ZG, Li DW, Fan J, Zhou J, Feng GS, Qiu SJ, Du CY. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. Oncotarget 2017;8:1774-87. [PMID: 27662665 DOI: 10.18632/oncotarget.12152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
2 Zuo C, Xia M, Wu Q, Zhu H, Liu J, Liu C. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett 2015;9:527-34. [PMID: 25624883 DOI: 10.3892/ol.2014.2727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
3 He X, Li J, Wu J, Zhang M, Gao P. Associations between activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like cytidine deaminase expression, hepatitis B virus (HBV) replication and HBV-associated liver disease (Review). Mol Med Rep 2015;12:6405-14. [PMID: 26398702 DOI: 10.3892/mmr.2015.4312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
4 Zhang Q, Ji XW, Hou XM, Lu FM, Du Y, Yin JH, Sun XY, Deng Y, Zhao J, Han X, Yang GS, Zhang HW, Chen XM, Shen HB, Wang HY, Cao GW. Effect of functional nuclear factor-kappaB genetic polymorphisms on hepatitis B virus persistence and their interactions with viral mutations on the risk of hepatocellular carcinoma. Ann Oncol 2014;25:2413-9. [PMID: 25223483 DOI: 10.1093/annonc/mdu451] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
5 Wang F, Long Q, Gong Y, Hu L, Zhang H, Oettgen P, Peng T. Epithelium-Specific ETS (ESE)-1 upregulated GP73 expression in hepatocellular carcinoma cells. Cell Biosci 2014;4:76. [PMID: 25530841 DOI: 10.1186/2045-3701-4-76] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Wang D, Li X, Li J, Lu Y, Zhao S, Tang X, Chen X, Li J, Zheng Y, Li S, Sun R, Yan M, Yu D, Cao G, Yang Y. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut 2019;68:1846-57. [PMID: 31154396 DOI: 10.1136/gutjnl-2018-317601] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
7 He XT, Xu HQ, Wang XM, He XS, Niu JQ, Gao PJ. Association between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2017; 23(2): 232-241 [PMID: 28127197 DOI: 10.3748/wjg.v23.i2.232] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Deng Y, Li P, Liu W, Pu R, Yang F, Song J, Yin J, Han X, Li C, Zhao J, Wang H, Cao G. The genetic polymorphism down-regulating HLA-DRB1 enhancer activity facilitates HBV persistence, evolution and hepatocarcinogenesis in the Chinese Han population. J Viral Hepat 2020;27:1150-61. [PMID: 32568442 DOI: 10.1111/jvh.13353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Ji X, Zhang Q, Li B, Du Y, Yin J, Liu W, Zhang H, Cao G. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma. Infection, Genetics and Evolution 2014;28:201-9. [DOI: 10.1016/j.meegid.2014.09.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
10 Gara SK, Tyagi MV, Patel DT, Gaskins K, Lack J, Liu Y, Kebebew E. GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3. Oncotarget 2020;11:3354-70. [PMID: 32934779 DOI: 10.18632/oncotarget.27703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lau KCK, Joshi SS, Mahoney DJ, Mason AL, van Marle G, Osiowy C, Coffin CS. Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants. Front Microbiol 2020;11:1653. [PMID: 32760388 DOI: 10.3389/fmicb.2020.01653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
12 Wangensteen KJ, Chang KM. Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:27-37. [PMID: 32737895 DOI: 10.1002/hep.31481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Chang LC, Kuo TY, Liu CW, Chen YS, Lin HH, Wu PF. APOBEC3G exerts tumor suppressive effects in human hepatocellular carcinoma. Anticancer Drugs 2014;25:456-61. [PMID: 24500029 DOI: 10.1097/CAD.0000000000000082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Singh H, Gangakhedkar RR. Occurrence of APOBEC3G variations in West Indian HIV patients. Microb Pathog 2018;121:325-30. [PMID: 29864532 DOI: 10.1016/j.micpath.2018.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Tian X, Zhang S, Zhang Q, Kang L, Ma C, Feng L, Li S, Li J, Yang L, Liu J, Qi Z, Shen Y. Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma. J Nutr Biochem 2020;85:108489. [PMID: 32827663 DOI: 10.1016/j.jnutbio.2020.108489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Yin J, Chen X, Li N, Han X, Liu W, Pu R, Wu T, Ding Y, Zhang H, Zhao J, Han X, Wang H, Cheng S, Cao G. Compartmentalized evolution of hepatitis B virus contributes differently to the prognosis of hepatocellular carcinoma. Carcinogenesis 2021;42:461-70. [PMID: 33247709 DOI: 10.1093/carcin/bgaa127] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Sui C, Dong Z, Yang C, Zhang M, Dai B, Geng L, Lu J, Yang J, Xu M. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma. J Cell Mol Med. 2019;23:6024-6033. [PMID: 31210410 DOI: 10.1111/jcmm.14465] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
18 Prasetyo AA, Sariyatun R, Reviono, Sari Y, Hudiyono, Haryati S, Adnan ZA, Hartono, Kageyama S. The APOBEC3B deletion polymorphism is associated with prevalence of hepatitis B virus, hepatitis C virus, Torque Teno virus, and Toxoplasma gondii co-infection among HIV-infected individuals. J Clin Virol 2015;70:67-71. [PMID: 26305823 DOI: 10.1016/j.jcv.2015.07.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
19 Ji X, Zhang Q, Du Y, Liu W, Li Z, Hou X, Cao G. Somatic mutations, viral integration and epigenetic modification in the evolution of hepatitis B virus-induced hepatocellular carcinoma. Curr Genomics. 2014;15:469-480. [PMID: 25646075 DOI: 10.2174/1389202915666141114213833] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
20 Wang H, Cao G, Fu J, Lv G. Hepatitis Viruses and Hepatoma. In: Bast RC, Hait WN, Kufe DW, Weichselbaum RR, Holland JF, Croce CM, Piccart-gebart M, Wang H, Hong WK, Pollock RE, editors. Holland-Frei Cancer Medicine. Hoboken: John Wiley & Sons, Inc.; 2016. pp. 1-6. [DOI: 10.1002/9781119000822.hfcm031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Pourshahian S. THERAPEUTIC OLIGONUCLEOTIDES, IMPURITIES, DEGRADANTS, AND THEIR CHARACTERIZATION BY MASS SPECTROMETRY. Mass Spectrom Rev 2021;40:75-109. [PMID: 31840864 DOI: 10.1002/mas.21615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Zhu X, Lei H, Wu J, Li JV, Tang H, Wang Y. Systemic responses of BALB/c mice to Salmonella typhimurium infection. J Proteome Res 2014;13:4436-45. [PMID: 25209111 DOI: 10.1021/pr500770x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
23 Luo X, Huang Y, Chen Y, Tu Z, Hu J, Tavis JE, Huang A, Hu Y. Association of Hepatitis B Virus Covalently Closed Circular DNA and Human APOBEC3B in Hepatitis B Virus-Related Hepatocellular Carcinoma. PLoS One 2016;11:e0157708. [PMID: 27310677 DOI: 10.1371/journal.pone.0157708] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
24 Du Y, Tao X, Wu J, Yu H, Yu Y, Zhao H. APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study. Cancer Cell Int 2018;18:78. [PMID: 29853799 DOI: 10.1186/s12935-018-0572-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
25 Du Y, Zhang YW, Pu R, Han X, Hu JP, Zhang HW, Wang HY, Cao GW. Phosphatase and tensin homologue genetic polymorphisms and their interactions with viral mutations on the risk of hepatocellular carcinoma. Chin Med J (Engl) 2015;128:1005-13. [PMID: 25881591 DOI: 10.4103/0366-6999.155057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
26 Lin J, Wu JF, Zhang Q, Zhang HW, Cao GW. Virus-related liver cirrhosis: Molecular basis and therapeutic options. World J Gastroenterol 2014; 20(21): 6457-6469 [PMID: 24914367 DOI: 10.3748/wjg.v20.i21.6457] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
27 Liu WB, Wu JF, Du Y, Cao GW. Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesis. Curr Oncol 2016;23:e49-56. [PMID: 26966413 DOI: 10.3747/co.23.2836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]